Pfizer (PFE) investors are bound to be disappointed with the stock’s returns. With a loss of 44%, it was among the worst-performing S&P 500 Index ($SPX) stocks last year. PFE stock peaked in December 2021, when its market cap surpassed $300 billion - and while the broader markets have since risen to new record highs, Pfizer’s market cap is only around half of what it once was at its peak. Though this might bring investors little comfort, sector peer Moderna (MRNA) – which also developed a COVID-19 vaccine – hasn’t fared any better, and its 2023 drawdown was similar to that of PFE.
Will Pfizer stock go up over the next couple of years, or will the pharma giant's shares remain dead money? Here’s the 2025 forecast for PFE, and the key catalysts that could drive a rally in the stock.
